Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer (Q57118558)

2 July 2019

title

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer (English)

1 reference

2 July 2019

main subject

metastatic breast cancer

1 reference

1 reference

2 July 2019

Steven Rosenberg

object named as

Steven A Rosenberg

1 reference

2 July 2019

Hui Xu

object named as

Hui Xu

1 reference

2 July 2019

author name string

Nikolaos Zacharakis

1 reference

2 July 2019

Harshini Chinnasamy

1 reference

2 July 2019

Mary Black

1 reference

2 July 2019

Zhili Zheng

1 reference

2 July 2019

Anna Pasetto

1 reference

2 July 2019

Michelle Langhan

1 reference

2 July 2019

Thomas Shelton

1 reference

2 July 2019

Todd Prickett

1 reference

2 July 2019

Jared Gartner

1 reference

2 July 2019

Li Jia

1 reference

2 July 2019

Katarzyna Trebska-McGowan

1 reference

2 July 2019

Robert P Somerville

1 reference

2 July 2019

Paul F Robbins

1 reference

2 July 2019

Stephanie L Goff

1 reference

2 July 2019

Steven A Feldman

1 reference

2 July 2019

language of work or name

English

0 references

publication date

4 June 2018

1 reference

2 July 2019

published in

Nature Medicine

1 reference

2 July 2019

volume

1 reference

2 July 2019

issue

1 reference

2 July 2019

page(s)

724-730

1 reference

2 July 2019

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Signatures of mutational processes in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Immunogenicity of somatic mutations in human gastrointestinal cancers.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

R.A. Fisher and the making of maximum likelihood 1912-1922

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0040-8

7 January 2021

10.1038/S41591-018-0040-8

Identifiers

DOI

1 reference

2 July 2019

PMC publication ID

6348479

1 reference

2 July 2019

PubMed publication ID

29867227

1 reference

2 July 2019